Cargando…

Impact of CYP2C9‐Interacting Drugs on Warfarin Pharmacogenomics

Precise dosing of warfarin is important to achieve therapeutic benefit without adverse effects. Pharmacogenomics explains some interindividual variability in warfarin response, but less attention has been paid to drug‐drug interactions in the context of genetic factors. We investigated retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agrawal, Saaket, Heiss, Meredith S., Fenter, Remington B., Abramova, Tatiana V., Perera, Minoli A., Pacheco, Jennifer A., Smith, Maureen E., Rasmussen‐Torvik, Laura J., George, Alfred L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485961/ https://www.ncbi.nlm.nih.gov/pubmed/32270628 http://dx.doi.org/10.1111/cts.12781

Ejemplares similares

Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
por: Grossniklaus, Daurice
Publicado: (2010)

Ethnic Diversity and Warfarin Pharmacogenomics
por: Asiimwe, Innocent G., et al.
Publicado: (2022)

Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
por: Wigle, Theodore J., et al.
Publicado: (2017)

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations(†)
por: Daly, Ann K., et al.
Publicado: (2017)

Verification of five pharmacogenomics-based warfarin administration models
por: Lin, Meiqin, et al.
Publicado: (2016)

A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9
por: Lee, Soo-Youn, et al.
Publicado: (2005)

CYP2C9 Mutation Affecting the Individual Variability of Warfarin Dose Requirement
por: Kim, Young Bum, et al.
Publicado: (2012)

The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)‐Warfarin
por: Wanounou, Maor, et al.
Publicado: (2022)

Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
por: Jia, LiQun, et al.
Publicado: (2017)

CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin
por: Karnik, Niteen D., et al.
Publicado: (2014)

Pharmacogenomic implications of the differential distribution of CYP2C9 metabolic phenotypes among Latin American populations
por: Suarez-Kurtz, Guilherme
Publicado: (2023)

The Contribution of VKORC1 and CYP2C9 Genetic Polymorphisms and Patients’ Demographic Characteristics with Warfarin Maintenance Doses: A Suggested Warfarin Dosing Algorithm
por: Khaleqsefat, Esmat, et al.
Publicado: (2020)

Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population
por: Hadjipanagi, Despina, et al.
Publicado: (2014)

Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry
por: Jarvis, Joseph P., et al.
Publicado: (2019)

Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction
por: Haug, Kari Bente Foss, et al.
Publicado: (2008)

VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients
por: Park, Sea Mi, et al.
Publicado: (2013)

Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy
por: Poopak, Behzad, et al.
Publicado: (2015)

Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine
por: Ayesh, Basim Mohammad, et al.
Publicado: (2018)

Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver
por: Klein, Kathrin, et al.
Publicado: (2010)

A Review of the Important Role of CYP2D6 in Pharmacogenomics
por: Taylor, Christopher, et al.
Publicado: (2020)

Distal Effect of Amino Acid Substitutions in CYP2C9 Polymorphic Variants Causes Differences in Interatomic Interactions against (S)-Warfarin
por: Lertkiatmongkol, Panida, et al.
Publicado: (2013)

The effect of CYP2C9*2, CYP2C9*3, and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah
por: Hosseinkhani, Zohreh, et al.
Publicado: (2018)

Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin
por: da Silveira, Maria Mariana Barros Melo, et al.
Publicado: (2019)

Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia
por: Giraldo-Ocampo, Sebastian, et al.
Publicado: (2023)

VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People
por: Henderson, Lindsay M., et al.
Publicado: (2019)

Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis
por: Jorgensen, Andrea L., et al.
Publicado: (2012)

Extremely Elevated International Normalized Ratio of Warfarin in a Patient with CYP2C9(*)1/(*)3 and Thyrotoxicosis
por: Lee, Ji Eun, et al.
Publicado: (2014)

Warfarin Dosing in a Patient with CYP2C9(∗)3(∗)3 and VKORC1-1639 AA Genotypes
por: Johnson, Mark, et al.
Publicado: (2014)

Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy
por: AL-Eitan, Laith N., et al.
Publicado: (2019)

The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population
por: Taşkın, Birce Dilge, et al.
Publicado: (2016)

Determination of Pleiotropic Effect of Warfarin in VKORC1 and CYP2C9 Genotypes in Patients With Heart Valve Replacement
por: Shafique, Huma, et al.
Publicado: (2022)

Applicability of Pharmacogenomically Guided Medication Treatment during Hospitalization of At-Risk Minority Patients
por: Saulsberry, Loren, et al.
Publicado: (2021)

Correction: Distal Effect of Amino Acid Substitutions in CYP2C9 Polymorphic Variants Causes Differences in Interatomic Interactions against (S)-Warfarin
por: Lertkiatmongkol, Panida, et al.
Publicado: (2013)

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
por: Takeuchi, Fumihiko, et al.
Publicado: (2009)

Global Pharmacogenomics: Distribution of CYP3A5 Polymorphisms and Phenotypes in the Brazilian Population
por: Suarez-Kurtz, Guilherme, et al.
Publicado: (2014)

Clinical significance of the series of CYP2C9*non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population
por: Wang, Dongxu, et al.
Publicado: (2022)

A patient-centered approach to the development and pilot of a warfarin pharmacogenomics patient education tool for health professionals
por: Barajas, Megan R., et al.
Publicado: (2015)

CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic
por: Dahabreh, Issa, et al.
Publicado: (2010)

CYP2D6 and CYP2C19 Variant Coverage of Commercial Antidepressant Pharmacogenomic Testing Panels Available in Victoria, Australia
por: Forbes, Malcolm, et al.
Publicado: (2023)

Pathway analysis of genome-wide data improves warfarin dose prediction
por: Daneshjou, Roxana, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vtmjgsbnr2ln272rjimrqgaklr